The clinical trial results indicate that utilizing ipilimumab at 1 and 3 mg/kg dosages effectively interrupted CTLA-4 signaling, resulting in anti-tumor activity in patients with B cell lymphoma [185]. Here, CTLA4 is linked to neoplasm.